Novavax Reports Q3 Revenue of $68.3 Million, Raises 2026 Guidance
Novavax reported a $31.4 million net loss, down 85% year over year, and raised its full-year 2026 non-GAAP adjusted total revenue guidance by $145 million to a $400 million midpoint. The increase includes a $125 million milestone payment earned in October after Sanofi began a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
Novavax, Inc. reported total revenue of $68.3 million for the third quarter of 2026, exceeding analyst expectations. The company's net loss narrowed to $31.4 million, representing an 85% improvement year-over-year, driven by reduced R&D and SG&A expenses. Novavax raised its full-year 2026 non-GAAP adjusted total revenue guidance by $145 million to a $400 million midpoint, supported by a $125 million milestone payment earned in October 2026 following Sanofi's initiation of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
Management highlighted the company's ongoing strategic execution, including the transition of commercial activities to Sanofi and a continued focus on cost-efficiency.